Headquartered in Saratoga, CA with subsidiaries in Bangalore, and Australia, Bugworks Research announced that the first human dose was administered in a phase 1 clinical trial. This trial to evaluate BWC0977, a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), was supported by Boston University's CARB-X -- Combating Antibiotic-Resistant Bacteria...
India’s Bugworks Secures U.S. Government Funding
Biotech innovator Bugworks Research which addresses anti-microbial resistance, secures funding from the Defense Threat Reduction Agency (DTRA) to support development of its novel broad-spectrum antibiotic BWC0977, against the most critical bacterial biothreats. Bugworks was set up in 2014 and incubated at the Centre for Cellular And Molecular Platforms, Bangalore. The...